Oyster Point Pharma, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$10.7M
Doctors Paid
18,427
Transactions
73,709
2024 Total
$3.3M
Payment Breakdown by Category
Research$5.7M (53.0%)
Food & Beverage$2.0M (19.1%)
Consulting$429,001 (4.0%)
Travel$284,650 (2.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.7M | 419 | 53.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.2M | 827 | 20.8% |
| Food and Beverage | $2.0M | 70,661 | 19.1% |
| Consulting Fee | $429,001 | 265 | 4.0% |
| Travel and Lodging | $284,650 | 1,524 | 2.7% |
| Honoraria | $28,725 | 8 | 0.3% |
| Space rental or facility fees (teaching hospital only) | $6,350 | 3 | 0.1% |
| Grant | $5,000 | 1 | 0.0% |
| Education | $3,500 | 1 | 0.0% |
Payments by Type
Research
$5.7M
419 transactions
General
$5.0M
73,290 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis | $2.0M | 0 | 95 |
| A PHASE 2, MULTICENTER, RANDOMIZED, CONTROLLED, DOUBLE-MASKED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF OC-01 (VARENICLINE) NASAL SPRAY IN SUBJECTS WITH NEUROTROPHIC KERATOPATHY (THE OLYMPIA STUDY) | $953,205 | 0 | 150 |
| A PHASE 2 MULTICENTER RANDOMIZED CONTROLLED DOUBLE-MASKED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF OC-01 (VARENICLINE) NASAL SPRAY IN SUBJECTS WITH NEUROTROPHIC KERATOPATHY (THE OLYMPIA STUDY) | $423,952 | 0 | 57 |
| A RANDOMIZED, CONTROLLED, DOUBLE-MASKED, TWO-ARM INVESTIGATOR-INITIATED STUDY TO ASSESS THE EFFICACY OF OC-01 (VARENICLINE) NASAL SPRAY ON SIGNS AND SYMPTOMS OF DRY EYE DISEASE IN SUBJECTS FOLLOWING LASER-ASSISTED IN SITU KERATOMILEUSIS (LASIK) | $381,088 | 0 | 3 |
| RANDOMIZED, CONTROLLED, DOUBLE-MASKED INVESTIGATOR INITIATED STUDY TO EVALUATE THE EFFICACY OF OC-01 (VARENICLINE) NASAL SPRAY ON OBJECTIVE AND SUBJECTIVE DRY EYE SIGNS AND SYMPTOMS IN DAILY DISPOSABLE CONTACT LENS WEARERS | $331,662 | 0 | 5 |
| A RANDOMIZED, CONTROLLED, DOUBLE-MASKED, TWO-ARM INVESTIGATOR-INITIATED STUDY TO ASSESS THE EFFICACY OF OC-01 (VARENICLINE) NASAL SPRAY ON SIGNS AND SYMPTOMS OF DRY EYE DISEASE IN SUBJECTS FOLLOWING CORNEAL COLLAGEN CROSSLINKING (CXL) | $158,140 | 0 | 2 |
| A RANDOMIZED, CONTROLLED, DOUBLE-MASKED, TWO-ARM INVESTIGATOR-INITIATED STUDY TO ASSESS THE EFFICACY OF OC-01 (VARENICLINE) NASAL SPRAY ON SIGNS AND SYMPTOMS OF DRY EYE DISEASE FOLLOWING PHOTOREFRACTIVE KERATECTOMY (PRK) | $157,653 | 0 | 2 |
| A SINGLE-ARM INVESTIGATOR INITIATED STUDY TO EVALUATE THE EFFICACY OF OC-01 (VARENICLINE SOLUTION) NASAL SPRAY ON SIGNS AND SYMPTOMS OF DRY EYE DISEASE IN SUBJECTS WITH SJOGREN'S SYNDROME | $112,465 | 0 | 4 |
| A Single-arm Investigator Initiated Study to Evaluate the Efficacy of OC-01 (varenicline solution) Nasal Spray on and symptoms of Dry Eye Disease in subjects with Sjogrens Syndrome (The SENSation Study) | $98,922 | 0 | 3 |
| A NATURAL HISTORY STUDY OF THE SIGNS OF BLEPHARITIS WITH BACTERIAL COLONIZATION OF THE LID MARGINS | $96,790 | 0 | 19 |
| AN INVESTIGATOR-INITIATED STUDY TO ASSESS THE ASSOCIATION OF DIABETIC RETINOPATHY SEVERITY SCALE (DRSS) WITH LEVEL OF DECREASED CORNEAL SENSITIVITY | $90,108 | 1 | 7 |
| A RANDOMIZED CONTROLLED DOUBLE-MASKED TWO-ARM INVESTIGATOR-INITIATED STUDY TO ASSESS THE EFFICACY OF OC-01 (VARENICLINE) NASAL SPRAY ON SIGNS AND SYMPTOMS OF DRY EYE DISEASE FOLLOWING PHOTOREFRACTIVE KERATECTOMY (PRK) | $83,280 | 0 | 1 |
| EVALUATION OF TEARS FROM SUBJECTS WITH DRY EYE DISEASE AS COMPARED TO TEARS FROM SUBJECTS WITH HEALTHY EYES | $82,500 | 0 | 1 |
| A RANDOMIZED CONTROLLED DOUBLE-MASKED TWO-ARM INVESTIGATOR-INITIATED STUDY TO ASSESS THE EFFICACY OF OC-01 (VARENICLINE) NASAL SPRAY ON SIGNS AND SYMPTOMS OF DRY EYE DISEASE IN SUBJECTS FOLLOWING LASER-ASSISTED IN SITU KERATOMILEUSIS (LASIK) | $71,763 | 0 | 2 |
| A Randomized, Controlled, Double-masked, Investigator-initiated Trial to Evaluate Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray | $68,977 | 0 | 2 |
| A PHASE 4 SINGLE-CENTER OPEN-LABEL STUDY EVALUATING THE SAFETY OF THE NASAL GUIDE UTILIZED DURING ADMINISTRATION WITH TYRVAYA | $60,925 | 0 | 5 |
| A SINGLE-CENTER RANDOMIZED OPEN-LABEL STUDY EVALUATING OC-01 (VARENICLINE SOLUTION) NASAL SPRAY COMPARED TO SYSTANE PRESERVATIVE FREE EYE DROPS FOR DYNAMIC OBJECTIVE AND QUANTIFABLE MUCO-AQUEOUS AND LIPID OUTCOMES ON TEAR FILM IMAGER NON-INVASIVE NANO IMAGING TECHNOLOGY IN SUBJECTS WITH DRY EYE DISEASE | $49,497 | 0 | 3 |
| A RANDOMIZED CONTROLLED DOUBLE-MASKED INVESTIGATOR-INITIATED TRIAL TO EVALUATE TEAR FILM QUALITY AND STABILITY IN SUJBECTS WITH DRY EYE DISEASE USING OC-01 (VARENICLINE SOLUTION) NASAL SPRAY 0.03 MG (OC-01 VNS) AS COMPARED TO VEHICLE CONTROL NASAL SPRAY. TEAR STABILITY USING NEUROACTIVATING MEDICAL INTERVENTION | $42,890 | 0 | 4 |
| A RANDOMIZED CONTROLLED DOUBLE-MASKED TWO-ARM INVESTIGATOR-INITIATED STUDY TO ASSESS THE EFFICACY OF OC-01 (VARENICLINE) NASAL SPRAY ON SIGNS AND SYMPTOMS OF DRY EYE DISEASE IN SUBJECTS FOLLOWING CORNEAL COLLAGEN CROSSLINKING (CXL) | $40,280 | 0 | 1 |
| RETROSPECTIVE ANALYSIS OF TYRVAYA ON SUBJECTS WITH DRY EYE DISEASE | $29,050 | 0 | 2 |
| EVALUATION AND CHARACTERIZATION OF OCULAR SURFACE CHANGES IN SUBJECTS UNDERGOING ANTI-VEGF INJECTIONS WITH NON-INVASIVE TEAR FILM IMAGER | $28,914 | 0 | 18 |
| A Phase 4, Single-Center, Open-Label Study Evaluating the Safety of the Tyrvaya Nasal Pump | $18,692 | 0 | 3 |
| Pooled by Severity | $15,215 | 5 | 5 |
| Retrospective Study with Tyrvaya and Sjogren's Syndrome | $14,260 | 0 | 1 |
| Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy | $12,944 | 0 | 3 |
| A RETROSPECTIVE REVIEW OF TYRVAYA USE IN SUBJECTS WITH DIAGNOSED SJOGREN'S DISEASE | $11,000 | 0 | 1 |
| A SINGLE-ARM INVESTIGATORINITIATED STUDY TO EVALUATE THEEFFICACY OF OC-01 (VARENICLINE SOLUTION) NASAL SPRAY ON REFRACTIVE ACCURACY AND SIGNS AND SYMPTOMS OF DRY EYE SUBJECTS UDNERGOING IOL IMPLANT CATARACT SURGERY | $9,250 | 0 | 1 |
| Pooled by Demographics | $6,678 | 2 | 2 |
| A PROSPECTIVE, CONTROLLED INVESTIGATOR-INITIATED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OC-01 (VARENICLINE SOLUTION) NASAL SPRAY IN SUBJECTS ON CONCOMITANT TOPICAL CYCLOSPORINE OPHTHALMIC MEDICATION THERAPY | $6,010 | 0 | 2 |
| NASAL SPRAY FOR THE TREATMENT OF DRY EYE DISEASE SIGNS AND SYMPTOMS IN SUBJECTS WITH AUTOIMMUNE DISEASE: INTEGRATED DATA FROM ONSET-1 AND ONSET-2 | $5,625 | 3 | 3 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Richard Adler, M.d, M.D | Specialist | Baltimore, MD | $217,472 | $0 |
| Dr. Anthony Realini, M.d, M.D | Ophthalmology | Morgantown, WV | $161,000 | $0 |
| Dr. Francis Mah, Md, MD | Specialist | Pittsburgh, PA | $142,731 | $0 |
| Rolando Toyos, M.d, M.D | Ophthalmology | Memphis, TN | $131,114 | $0 |
| Dr. Sheri Rowen, Md, MD | Ophthalmology | Newport Beach, CA | $125,203 | $0 |
| Mark Milner, Md, MD | Ophthalmology | Palm Beach Gardens, FL | $104,473 | $0 |
| Dr. Laura Periman, Md, MD | Cornea and External Diseases Specialist | Seattle, WA | $103,594 | $0 |
| Dr. Pamela Theriot, O.d, O.D | Optometrist | Shreveport, LA | $97,131 | $0 |
| Preeya Gupta, Md, MD | Ophthalmology | Raleigh, NC | $96,986 | $0 |
| Damon Dierker, O.d, O.D | Optometrist | Indianapolis, IN | $83,544 | $0 |
| Douglas Devries, O.d, O.D | Optometrist | Sparks, NV | $80,597 | $0 |
| Dr. Marc Bloomenstein, Od, OD | Corneal and Contact Management | Scottsdale, AZ | $80,251 | $0 |
| Selina Mcgee, O.d, O.D | Optometrist | Edmond, OK | $67,825 | $0 |
| Darrell White, Md, MD | Ophthalmology | Westlake, OH | $62,960 | $0 |
| Dr. Marjan Farid, Md, MD | Ophthalmology | Irvine, CA | $59,327 | $0 |
| Dr. Ravi Patel, M.d, M.D | Ophthalmology | Eatontown, NJ | $54,714 | $0 |
| Dr. Mitchell Jackson, Md, MD | Ophthalmology | Lake Villa, IL | $53,715 | $0 |
| Jessica Steen, O.d, O.D | Optometrist | Davie, FL | $52,148 | $0 |
| Dr. Jai Parekh, M.d, M.D | Ophthalmology | Woodland Park, NJ | $48,269 | $0 |
| Joshua Johnston, Od, OD | Optometrist | Atlanta, GA | $46,485 | $0 |
| Walter Whitley, Md, MD | Optometrist | Norfolk, VA | $37,331 | $0 |
| Inder Singh | Ophthalmology | Racine, WI | $36,558 | $0 |
| Dr. John Sheppard, M.d, M.D | Ophthalmology | Norfolk, VA | $34,675 | $0 |
| Dr. Kristen Brown, O.d, O.D | Optometrist | Boston, MA | $33,983 | $0 |
| Dr. Nathan Radcliffe, M.d, M.D | Ophthalmology | New York, NY | $33,518 | $0 |
About Oyster Point Pharma, Inc.
Oyster Point Pharma, Inc. has made $10.7M in payments to 18,427 healthcare providers, recorded across 73,709 transactions in the CMS Open Payments database. In 2024, the company paid $3.3M. The top product by payment volume is TYRVAYA ($5.2M).
Payments were distributed across 88 medical specialties. The top specialty by payment amount is Ophthalmology ($2.1M to 4,996 doctors).
Payment categories include: Food & Beverage ($2.0M), Consulting ($429,001), Research ($5.7M), Travel & Lodging ($284,650).
Oyster Point Pharma, Inc. is associated with 2 products in the CMS Open Payments database.